TITLE

FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes

AUTHOR(S)
Kesselheim, AS; Darrow, JJ
PUB. DATE
January 2015
SOURCE
Clinical Pharmacology & Therapeutics;Jan2015, Vol. 97 Issue 1, p29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
New prescription drugs receive approval from the US Food and Drug Administration (FDA) based on tests establishing safety and adequate and well-controlled trials demonstrating 'substantial evidence' of efficacy. However, a number of legislative and regulatory initiatives, the most recent being the breakthrough therapy designation created in 2012, give the FDA flexibility to approve drugs on the basis of less rigorous data in situations of greater clinical need. These expedited development and review pathways now contribute to a majority of all new drug approvals and have important benefits in encouraging efficient availability of transformative drugs. They also have a number of risks, including a heightened possibility that the drugs will be discovered to be ineffective or unsafe after widespread use, and confusion by patients and physicians over what it means for a product to be 'FDA approved.'
ACCESSION #
100371542

 

Related Articles

  • No Strings Attached. Peters, Rita C. // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p4 

    The author discusses the implications of the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. She explains that the legislation must be renewed before its expiration date on September 30, 2012 because it may compromise the drug review process and may force the Food and...

  • The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context. Royall, M. Sean; Lipton, Joshua // Antitrust Magazine;Spring2010, Vol. 24 Issue 2, p22 

    The article focuses on the complexities involved in litigating generic drug exclusion claims made by the branded pharmaceutical manufacturers under the U.S. antitrust law. It discusses the Hatch-Waxman Act which permits a generic manufacturer to file an Abbreviated New Drug Application, to be...

  • From Molecule to Medicine Cabinet: A Drug's Long Journey from Development to Approval. Onofrey, Bruce E. // Review of Optometry;Jun2013, Vol. 150 Issue 6, p26 

    The article focuses on the drug approval process of the U.S. Food and Drug Administration. It states that first step is preclinical studies in which the molecule is tested on animals and then an Investigational New Drug Application (IND) is filed to FDA to get approval for starting clinical...

  • Drug Watch.  // Formulary;Feb2004, Vol. 39 Issue 2, p124 

    Presents various antidepressant agents in late-stage development and approval by the U.S. Food and Drug Administration as of February 2004. New drugs; Latest indications/combinations/formulations; Information resouces on drug development.

  • What YOU Need to Know About QbR. Ciurczak, Emil W. // Contract Pharma;Jun2014, Vol. 16 Issue 5, p96 

    The article offers information on the question-based review (QBR) format of the U.S. Food and Drug Administration (FDA) for submitting information necessary in amended new drug applications (ANDAs). Among the information required are the drug substance's manufacturer, characterization, and...

  • Plexxikon's Speedy Zelboraf Work Helped by Diagnostic.  // Bioworld Week;8/22/2011, Vol. 19 Issue 33, p1 

    The article reports on the approval of cancer drug, Zelboraf, from Plexxikon Inc. by the U.S. Food and Drug Administration (FDA) in 2011. It states that in a Phase I extension study conducted in 2009, Zelboraf shows 81% response rate. It indicates that the success of the Phase I study results in...

  • Getting it to the streets. Wiegler, Laurie // TCE: The Chemical Engineer;Jun2009, Issue 816, p44 

    The article discusses the impact of the hasty approval of drugs by the U.S. Food and Drug Administration (FDA) on people. According to some critics, there are drug companies that hide negative test results and bribe doctors and scientists on the FDA panel. It mentions unmet medical need as a key...

  • Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation. Rising, Kristin; Bacchetti, Peter; Bero, Lisa // PLoS Medicine;Nov2008, Vol. 5 Issue 11, pe217 

    Lisa Bero and colleagues review the publication status of all efficacy trials carried out in support of new drug approvals from 2001 and 2002, and find that a quarter of trials remain unpublished.

  • Eliminating the U.S. drug lag: Implications for drug safety. Olson, Mary // Journal of Risk & Uncertainty;Aug2013, Vol. 47 Issue 1, p1 

    An increase in new drugs first launched in the U.S. and shorter lags between first global drug launch and U.S. approval indicate that the U.S. drug lag has declined. This paper examines the impact of these changes on drug safety using adverse drug reaction data for FDA-approved drugs in 1990 to...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics